Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis

Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis

Background: This study investigates the potential predictors of nivolumab plus chemotherapy or multitarget tyrosine kinase inhibitor (TKI) treatment response in patients with recurrent hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).Methods: Patients with recurrent hepatitis B virus-r...

Full description

Bibliographic Details
Main Authors: Chao Chen, Li An, Ying Cheng, Xianwen Luo, Zixiong Li, Xiufeng Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
hepatitis B virus
nivolumab
chemotherapy
tyrosine kinase inhibitor
programmed cell death protein 1
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01404/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01404/full

Similar Items